SV106 · SV-Delivery™
SV106 Delivery™ Human CD8 T cell targeted LNP
★ 最相关 in vivo CAR-T 探索的 kit
Species
Human
Primary target
CD8 T cell (human)
Applications
in vitro / ex vivo
Cargo compatibility
mRNA, saRNA
Particle size
—
Freeze-thaw cycles tested
—
Published efficacy
Each result is shown with its evidence grade and source. Grade D entries are not displayed in production.
| Assay | Result | Grade | Source |
|---|---|---|---|
| Human CD8 T cell in vitro (推测) | ~80% GFP+ (与 mouse 类似 lipid family) | C | Inferred from SV105 data + cross-species lipid family |
Recommended in vitro dose
2-10 μg / 10⁶ cells
Highlights
- 可用于 in vivo CAR-T 探索 · 但仍 research-grade
- 适合 ex vivo CAR-T enhancement studies
Known limitations
Honest disclosure: these are gaps in current SunVax data, not intended performance claims.
- GMP transition 还未完成
- Cargo > 5kb 性能待测
Sources used on this page
- SunVax conference presentation 2026-05-03 · slide 2 (kits portfolio) and slide 3 (efficacy / stability data).
- SunVax product catalog at sunvaxmrna.com (last verified 2026-05-16).
- Per-result citations are shown in the "Published efficacy" table above with their evidence grade.
To request a correction or to ask for additional documentation on this kit, email yingzhongli@sunvaxmrna.com.